VERU VERU INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 863894 · Fiscal year ends 09/30
Financial factors as of 2024-09-30 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.6%
TTM net income YoY59.4%
TTM EPS YoY—
Revenue 3-yr CAGR-34.9%
Net income 3-yr CAGR—
Margins
Gross margin34.7%
Operating margin-214.2%
Net margin-223.9%
FCF margin-129.3%
EBITDA margin-213.0%
Returns
ROE-145.4%
ROA-68.5%
ROIC (approx.)-327.4%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets46.5%
Debt / equity0.00x
Current ratio2.97x
Interest coverage-59.54x
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-29.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | $16.89M |
| Cost of revenue | — | $11.03M |
| Gross profit | — | $5.85M |
| R&D expense | $15.59M | $12.78M |
| SG&A expense | $19.94M | $24.61M |
| Operating income | -$24.75M | -$36.17M |
| Interest expense | — | $607,470 |
| Income tax | $0 | $0 |
| Net income | -$22.73M | -$37.80M |
| EBITDA | -$24.60M | -$35.90M |
| EPS (basic) | -1.55 | -2.80 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $15.79M | $24.92M |
| Receivables | — | $3.96M |
| Inventory | — | $4.14M |
| Current assets | $18.92M | $35.22M |
| PP&E, net | $364,808 | $481,372 |
| Goodwill | $6.88M | $6.88M |
| Intangibles | — | $0 |
| Total assets | $29.84M | $60.42M |
| Current liabilities | $7.79M | $11.87M |
| Total liabilities | $11.50M | $28.10M |
| Shareholders' equity | $18.33M | $32.32M |
| Shares outstanding | 14.65M | 14.64M |
| Cash flow statement | ||
| Operating cash flow | -$30.04M | -$21.68M |
| Capital expenditure | $1,083 | $158,322 |
| Free cash flow | -$30.04M | -$21.84M |
| Investing cash flow | $25.14M | $146,214 |
| Financing cash flow | -$4.22M | $36.83M |
| Depreciation & amortization | $152,105 | $268,177 |
| Stock-based compensation | $8.10M | $13.64M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.